Cardio-Oncology

Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association

Umberto Campia, Javid J. Moslehi, Laleh Amiri-Kordestani, Ana Barac, Joshua A. Beckman, David D. Chism, Paul Cohen, John D. Groarke, Joerg Herrmann, Carolyn M. Reilly, Neal Lee Weintraub

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cardio-oncology has organically developed as a new discipline within cardiovascular medicine as a result of the cardiac and vascular adverse sequelae of the major advances in cancer treatment. Patients with cancer and cancer survivors are at increased risk of vascular disease for a number of reasons. First, many new cancer therapies, including several targeted therapies, are associated with vascular and metabolic complications. Second, cancer itself serves as a risk factor for vascular disease, especially by increasing the risk for thromboembolic events. Finally, recent data suggest that common modifiable and genetic risk factors predispose to both malignancies and cardiovascular disease. Vascular complications in patients with cancer represent a new challenge for the clinician and a new frontier for research and investigation. Indeed, vascular sequelae of novel targeted therapies may provide insights into vascular signaling in humans. Clinically, emerging challenges are best addressed by a multidisciplinary approach in which cardiovascular medicine specialists and vascular biologists work closely with oncologists in the care of patients with cancer and cancer survivors. This novel approach realizes the goal of providing superior care through the creation of cardio-oncology consultative services and the training of a new generation of cardiovascular specialists with a broad understanding of cancer treatments.

Original languageEnglish (US)
Pages (from-to)e579-e602
JournalCirculation
Volume139
Issue number13
DOIs
StatePublished - Mar 26 2019

Fingerprint

Blood Vessels
Neoplasms
Vascular Diseases
Survivors
Therapeutics
Second Primary Neoplasms
Cardiology
Patient Care
Cardiovascular Diseases
Medicine
Research

Keywords

  • AHA Scientific Statements
  • cardiovascular diseases
  • medical oncology
  • therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Cardio-Oncology : Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. / Campia, Umberto; Moslehi, Javid J.; Amiri-Kordestani, Laleh; Barac, Ana; Beckman, Joshua A.; Chism, David D.; Cohen, Paul; Groarke, John D.; Herrmann, Joerg; Reilly, Carolyn M.; Weintraub, Neal Lee.

In: Circulation, Vol. 139, No. 13, 26.03.2019, p. e579-e602.

Research output: Contribution to journalArticle

Campia, U, Moslehi, JJ, Amiri-Kordestani, L, Barac, A, Beckman, JA, Chism, DD, Cohen, P, Groarke, JD, Herrmann, J, Reilly, CM & Weintraub, NL 2019, 'Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association', Circulation, vol. 139, no. 13, pp. e579-e602. https://doi.org/10.1161/CIR.0000000000000641
Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD et al. Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. Circulation. 2019 Mar 26;139(13):e579-e602. https://doi.org/10.1161/CIR.0000000000000641
Campia, Umberto ; Moslehi, Javid J. ; Amiri-Kordestani, Laleh ; Barac, Ana ; Beckman, Joshua A. ; Chism, David D. ; Cohen, Paul ; Groarke, John D. ; Herrmann, Joerg ; Reilly, Carolyn M. ; Weintraub, Neal Lee. / Cardio-Oncology : Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. In: Circulation. 2019 ; Vol. 139, No. 13. pp. e579-e602.
@article{7b7c1f16f92b479796965c923b7393c2,
title = "Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association",
abstract = "Cardio-oncology has organically developed as a new discipline within cardiovascular medicine as a result of the cardiac and vascular adverse sequelae of the major advances in cancer treatment. Patients with cancer and cancer survivors are at increased risk of vascular disease for a number of reasons. First, many new cancer therapies, including several targeted therapies, are associated with vascular and metabolic complications. Second, cancer itself serves as a risk factor for vascular disease, especially by increasing the risk for thromboembolic events. Finally, recent data suggest that common modifiable and genetic risk factors predispose to both malignancies and cardiovascular disease. Vascular complications in patients with cancer represent a new challenge for the clinician and a new frontier for research and investigation. Indeed, vascular sequelae of novel targeted therapies may provide insights into vascular signaling in humans. Clinically, emerging challenges are best addressed by a multidisciplinary approach in which cardiovascular medicine specialists and vascular biologists work closely with oncologists in the care of patients with cancer and cancer survivors. This novel approach realizes the goal of providing superior care through the creation of cardio-oncology consultative services and the training of a new generation of cardiovascular specialists with a broad understanding of cancer treatments.",
keywords = "AHA Scientific Statements, cardiovascular diseases, medical oncology, therapeutics",
author = "Umberto Campia and Moslehi, {Javid J.} and Laleh Amiri-Kordestani and Ana Barac and Beckman, {Joshua A.} and Chism, {David D.} and Paul Cohen and Groarke, {John D.} and Joerg Herrmann and Reilly, {Carolyn M.} and Weintraub, {Neal Lee}",
year = "2019",
month = "3",
day = "26",
doi = "10.1161/CIR.0000000000000641",
language = "English (US)",
volume = "139",
pages = "e579--e602",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Cardio-Oncology

T2 - Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association

AU - Campia, Umberto

AU - Moslehi, Javid J.

AU - Amiri-Kordestani, Laleh

AU - Barac, Ana

AU - Beckman, Joshua A.

AU - Chism, David D.

AU - Cohen, Paul

AU - Groarke, John D.

AU - Herrmann, Joerg

AU - Reilly, Carolyn M.

AU - Weintraub, Neal Lee

PY - 2019/3/26

Y1 - 2019/3/26

N2 - Cardio-oncology has organically developed as a new discipline within cardiovascular medicine as a result of the cardiac and vascular adverse sequelae of the major advances in cancer treatment. Patients with cancer and cancer survivors are at increased risk of vascular disease for a number of reasons. First, many new cancer therapies, including several targeted therapies, are associated with vascular and metabolic complications. Second, cancer itself serves as a risk factor for vascular disease, especially by increasing the risk for thromboembolic events. Finally, recent data suggest that common modifiable and genetic risk factors predispose to both malignancies and cardiovascular disease. Vascular complications in patients with cancer represent a new challenge for the clinician and a new frontier for research and investigation. Indeed, vascular sequelae of novel targeted therapies may provide insights into vascular signaling in humans. Clinically, emerging challenges are best addressed by a multidisciplinary approach in which cardiovascular medicine specialists and vascular biologists work closely with oncologists in the care of patients with cancer and cancer survivors. This novel approach realizes the goal of providing superior care through the creation of cardio-oncology consultative services and the training of a new generation of cardiovascular specialists with a broad understanding of cancer treatments.

AB - Cardio-oncology has organically developed as a new discipline within cardiovascular medicine as a result of the cardiac and vascular adverse sequelae of the major advances in cancer treatment. Patients with cancer and cancer survivors are at increased risk of vascular disease for a number of reasons. First, many new cancer therapies, including several targeted therapies, are associated with vascular and metabolic complications. Second, cancer itself serves as a risk factor for vascular disease, especially by increasing the risk for thromboembolic events. Finally, recent data suggest that common modifiable and genetic risk factors predispose to both malignancies and cardiovascular disease. Vascular complications in patients with cancer represent a new challenge for the clinician and a new frontier for research and investigation. Indeed, vascular sequelae of novel targeted therapies may provide insights into vascular signaling in humans. Clinically, emerging challenges are best addressed by a multidisciplinary approach in which cardiovascular medicine specialists and vascular biologists work closely with oncologists in the care of patients with cancer and cancer survivors. This novel approach realizes the goal of providing superior care through the creation of cardio-oncology consultative services and the training of a new generation of cardiovascular specialists with a broad understanding of cancer treatments.

KW - AHA Scientific Statements

KW - cardiovascular diseases

KW - medical oncology

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85063712295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063712295&partnerID=8YFLogxK

U2 - 10.1161/CIR.0000000000000641

DO - 10.1161/CIR.0000000000000641

M3 - Article

VL - 139

SP - e579-e602

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 13

ER -